TP53 and colorectal carcinoma: The preferential cytotoxicity toward both wild-type and mutant p53 CRC cells, particularly the p53-wild-type HCT116, and the relatively lower toxicity in normal cells support the potential development of SA and SN as selective anticancer agents.